Fixed-dose combinations (FDCs): A strong offense in chronic disease management 2

According to The American Journal of Medicine2:
  • Noncompliance to medication regimens is reduced by 24% to 26% with FDC regimens

  • FDCs should be considered in patients with chronic conditions like hypertension

  • FDCs improve medication compliance, which can translate into better clinical outcomes
When monotherapy is inadequate or multiple drugs are likely needed to control high blood pressure...
Introducing PRESTALIA® (perindopril arginine and amlodipine)—the first SPC of perindopril arginine and amlodipine besylate for the treatment of hypertension.1
Rapid and sustained BP control
The antihypertensive effects of PRESTALIA was studied in the PATH (Perindopril and Amlodipine in Treatment of Hypertension) trial.1
PRESTALIA 14/10 mg
The highest strength of PRESTALIA 14/10 mg was studied in 837 patients in a 6-week, double-blind, active-controlled clinical trial. Patients with a seated diastolic pressure of 95 to 115 mm Hg received treatments of PRESTALIA 14/10 mg, perindopril erbumine 16 mg, or amlodipine 10 mg once daily for 6 weeks.

The study demonstrated that PRESTALIA 14/10 mg produced statistically significantly greater reductions in blood pressure compared to both monotherapies at Week 6.

PRESTALIA 14/10 mg increased the likelihood of achieving target clinic systolic and diastolic blood pressure control compared to monotherapy with either perindopril erbumine or amlodipine. See chart below.

Reduction of CV events
Lowering blood pressure reduces the risk of cardiovascular events, like strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs, including amlodipine and perindopril—the components of PRESTALIA.1
  1. PRESTALIA [package insert]. Cincinnati, OH: Symplmed, LLC; 2015.
  2. Bangalore S, Kamalakkannan G, Parkar S, Messerli, FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med.:2007; 120(8) 713-719.